Greenwich LifeSciences, Inc. (GLSI) Stock Price
GLSIStock
$14.55+49.69%52W
Market Cap$213.57M
P/E—
PEG Ratio—
Div yield—
Beta1.55
GLSI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.99%
Price vs S&P 500 (4W)-20.43%
VGM Score56.23
GLSI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.33 | -$0.27 | +18.18%(+$0.06) | |
| Q1 2026 | -$0.35 | -$0.39 | -11.43%(-$0.04) | |
| Q4 2025 | -$0.32 | -$0.58 | -81.25%(-$0.26) | |
| Q3 2025 | -$0.36 | -$0.30 | +16.67%(+$0.06) | |
| Q2 2025 | -$0.24 | -$0.30 | -25.00%(-$0.06) |
GLSI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
GLSIGreenwich LifeSciences, Inc. | — | — | C | — | — | — | — | $14.55 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in patients with HER2/neu-expressing tumors, which represent approximately 75% of breast cancers. The company is advancing GLSI-100 through its Phase III Flamingo-01 trial and expanding operations into Europe with plans to establish up to 150 clinical trial sites globally.